KKR to invest $200m in Indian drug maker Gland Pharma
KKR has agreed to buy a minority stake in Gland Pharma, an Indian injectable drugs manufacturer, for approximately $200 million. The investment facilitates the exit of Invascent Capital's Evolvence India Life Sciences Fund (EILSF).
The size of the stake was not disclosed, but sources familiar with the transaction put it at between 35% and 40%. The deal will be structured in two parts: an infusion of fresh equity followed by the purchase...
More on South Asia
Latest News
Asian GPs slow implementation of ESG policies - survey
Asia-based private equity firms are assigning more dedicated resources to environment, social, and governance (ESG) programmes, but policy changes have slowed in the past 12 months, in part due to concerns raised internally and by LPs, according to a...
Singapore fintech start-up LXA gets $10m seed round
New Enterprise Associates (NEA) has led a USD 10m seed round for Singapore’s LXA, a financial technology start-up launched by a former Asia senior executive at The Blackstone Group.
India's InCred announces $60m round, claims unicorn status
Indian non-bank lender InCred Financial Services said it has received INR 5bn (USD 60m) at a valuation of at least USD 1bn from unnamed investors including “a global private equity fund.”
Insight leads $50m round for Australia's Roller
Insight Partners has led a USD 50m round for Australia’s Roller, a venue management software provider specializing in family fun parks.